Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425835 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL31614958 | 0.84 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL2064221 | 0.82 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL702012 | 0.80 | CES2 (0.37) | CES2CES1GABRA1GABRG2GABRB3 | |
| SCHEMBL30368120 | 0.80 | CES2 (0.37) | CES2CES1GABRA1GABRG2GABRB3 | |
| SCHEMBL11932846 | 0.80 | AXL (0.31) | — | |
| SCHEMBL31614969 | 0.80 | — | — | |
| SCHEMBL29279709 | 0.80 | MEP1B (0.37) | DRD4 | |
| SCHEMBL25049411 | 0.79 | CYP1A2 (0.31) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL30210991 | 0.79 | CYP1A2 (0.31) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4577214-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-118302162-A | Small molecule inhibitors of KRAS muteins | 默沙东有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117820333-A | KRAS G12C inhibitors | 伊莱利利公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117794918-A | Substituted tetrahydrofuran analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-117500799-A | Substituted fused azines as KRAS G12D inhibitors | 伊莱利利公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-114621135-B | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-114828964-B | KRAS G12C inhibitors | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-112300120-B | Compound for preparing balsalavir or derivatives thereof, preparation method and application thereof | 北京四环制药有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114828964-A | KRAS G12C inhibitors | 伊莱利利公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114621135-A | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, TRPA1 | CYP1A2 1276/4885CYP2D6 816/4885CYP2C9 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.